| 2025년 12월 17일 2025년 12월 19일 제출 | Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner | J Other acquisition or disposition (describe transaction) Common Stock | 처분(D) | 148,153 | 11.00 | 1,629,683 산출: 주식 수 × 주당 가격. 정확한 값 1629683.00. | 0 | 간접(I) See Footnote | 아니요 | F1, F2 - F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
- F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
| 제출 문서 열기 0001104659-25-123156 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2025년 12월 17일 2025년 12월 19일 제출 | Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner | J Other acquisition or disposition (describe transaction) 파생증권: Prefunded Warrants — 기초자산 Common Stock (433,962) — 행사가 0.0001 | 처분(D) | 433,962 | 10.999 | 4,773,148.038 산출: 주식 수 × 주당 가격. 정확한 값 4773148.038. | 0 | 간접(I) See Footnote | 아니요 | F1, F2 - F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
- F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
| 제출 문서 열기 0001104659-25-123156 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2025년 12월 17일 2025년 12월 19일 제출 | Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner | J Other acquisition or disposition (describe transaction) 파생증권: Series A Common Stock Purchase Warrants — 기초자산 Common Stock (117,019) — 행사가 8.16 | 처분(D) | 117,019 | 4.71 | 551,159.49 산출: 주식 수 × 주당 가격. 정확한 값 551159.49. | 0 | 간접(I) See Footnote | 아니요 | F1, F2 - F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
- F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
| 제출 문서 열기 0001104659-25-123156 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2025년 12월 17일 2025년 12월 19일 제출 | Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner | J Other acquisition or disposition (describe transaction) 파생증권: Series C Common Stock Purchase Warrants — 기초자산 Common Stock (117,019) — 행사가 8.16 | 처분(D) | 117,019 | 4.71 | 551,159.49 산출: 주식 수 × 주당 가격. 정확한 값 551159.49. | 0 | 간접(I) See Footnote | 아니요 | F1, F2 - F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
- F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
| 제출 문서 열기 0001104659-25-123156 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2025년 12월 17일 2025년 12월 19일 제출 | Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner | J Other acquisition or disposition (describe transaction) 파생증권: Amended Series A Common Stock Purchase Warrants — 기초자산 Common Stock (158,531) — 행사가 0.01 | 처분(D) | 158,531 | 10.99 | 1,742,255.69 산출: 주식 수 × 주당 가격. 정확한 값 1742255.69. | 0 | 간접(I) See Footnote | 아니요 | F1, F2 - F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
- F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
| 제출 문서 열기 0001104659-25-123156 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2025년 12월 17일 2025년 12월 19일 제출 | Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner | J Other acquisition or disposition (describe transaction) 파생증권: Amended Series C Common Stock Purchase Warrants — 기초자산 Common Stock (250,627) — 행사가 0.01 | 처분(D) | 250,627 | 10.99 | 2,754,390.73 산출: 주식 수 × 주당 가격. 정확한 값 2754390.73. | 0 | 간접(I) See Footnote | 아니요 | F1, F2 - F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
- F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
| 제출 문서 열기 0001104659-25-123156 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2025년 12월 17일 2025년 12월 17일 제출 | Hill Malcolm R Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 파생증권: Stock Option (Right to Buy) — 기초자산 Common Stock (1,218) — 행사가 5.41 | 처분(D) | 1,218 | — | — | 0 | 직접(D) | 아니요 | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| 제출 문서 열기 0001193125-25-322642 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2025년 12월 17일 2025년 12월 17일 제출 | Hill Malcolm R Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 파생증권: Stock Option (Right to Buy) — 기초자산 Common Stock (5,833) — 행사가 4.45 | 처분(D) | 5,833 | — | — | 0 | 직접(D) | 아니요 | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| 제출 문서 열기 0001193125-25-322642 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2025년 12월 17일 2025년 12월 17일 제출 | Hill Malcolm R Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 파생증권: Stock Option (Right to Buy) — 기초자산 Common Stock (1,218) — 행사가 3.453 | 처분(D) | 1,218 | — | — | 0 | 직접(D) | 아니요 | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| 제출 문서 열기 0001193125-25-322642 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2025년 12월 17일 2025년 12월 17일 제출 | GARNER CAM L Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 파생증권: Stock Option (Right to Buy) — 기초자산 Common Stock (1,479) — 행사가 5.41 | 처분(D) | 1,479 | — | — | 0 | 직접(D) | 아니요 | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| 제출 문서 열기 0001193125-25-322643 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2025년 12월 17일 2025년 12월 17일 제출 | GARNER CAM L Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 파생증권: Stock Option (Right to Buy) — 기초자산 Common Stock (8,750) — 행사가 4.45 | 처분(D) | 8,750 | — | — | 0 | 직접(D) | 아니요 | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| 제출 문서 열기 0001193125-25-322643 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2025년 12월 17일 2025년 12월 17일 제출 | GARNER CAM L Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 파생증권: Stock Option (Right to Buy) — 기초자산 Common Stock (1,291) — 행사가 3.453 | 처분(D) | 1,291 | — | — | 0 | 직접(D) | 아니요 | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| 제출 문서 열기 0001193125-25-322643 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2025년 12월 17일 2025년 12월 17일 제출 | WIDDER KENNETH J Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 파생증권: Stock Option (Right to Buy) — 기초자산 Common Stock (1,187) — 행사가 5.41 | 처분(D) | 1,187 | — | — | 0 | 직접(D) | 아니요 | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| 제출 문서 열기 0001193125-25-322641 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2025년 12월 17일 2025년 12월 17일 제출 | WIDDER KENNETH J Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 파생증권: Stock Option (Right to Buy) — 기초자산 Common Stock (5,833) — 행사가 4.45 | 처분(D) | 5,833 | — | — | 0 | 직접(D) | 아니요 | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| 제출 문서 열기 0001193125-25-322641 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2025년 12월 17일 2025년 12월 17일 제출 | WIDDER KENNETH J Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 파생증권: Stock Option (Right to Buy) — 기초자산 Common Stock (1,187) — 행사가 3.453 | 처분(D) | 1,187 | — | — | 0 | 직접(D) | 아니요 | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| 제출 문서 열기 0001193125-25-322641 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2025년 12월 17일 2025년 12월 17일 제출 | REED VICKIE S Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 파생증권: Stock Option (Right to Buy) — 기초자산 Common Stock (1,250) — 행사가 5.41 | 처분(D) | 1,250 | — | — | 0 | 직접(D) | 아니요 | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| 제출 문서 열기 0001193125-25-322638 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2025년 12월 17일 2025년 12월 17일 제출 | REED VICKIE S Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 파생증권: Stock Option (Right to Buy) — 기초자산 Common Stock (5,833) — 행사가 4.45 | 처분(D) | 5,833 | — | — | 0 | 직접(D) | 아니요 | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| 제출 문서 열기 0001193125-25-322638 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2025년 12월 17일 2025년 12월 17일 제출 | REED VICKIE S Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 파생증권: Stock Option (Right to Buy) — 기초자산 Common Stock (1,250) — 행사가 3.453 | 처분(D) | 1,250 | — | — | 0 | 직접(D) | 아니요 | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| 제출 문서 열기 0001193125-25-322638 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2025년 12월 17일 2025년 12월 17일 제출 | Brady Todd C Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 파생증권: Stock Option (Right to Buy) — 기초자산 Common Stock (1,218) — 행사가 5.41 | 처분(D) | 1,218 | — | — | 0 | 직접(D) | 아니요 | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| 제출 문서 열기 0001193125-25-322639 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2025년 12월 17일 2025년 12월 17일 제출 | Brady Todd C Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 파생증권: Stock Option (Right to Buy) — 기초자산 Common Stock (5,833) — 행사가 4.45 | 처분(D) | 5,833 | — | — | 0 | 직접(D) | 아니요 | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| 제출 문서 열기 0001193125-25-322639 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2025년 12월 17일 2025년 12월 17일 제출 | Brady Todd C Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 파생증권: Stock Option (Right to Buy) — 기초자산 Common Stock (1,187) — 행사가 3.453 | 처분(D) | 1,187 | — | — | 0 | 직접(D) | 아니요 | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| 제출 문서 열기 0001193125-25-322639 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2025년 12월 17일 2025년 12월 17일 제출 | Smeal Benjamin C. Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 파생증권: Stock Option (Right to Buy) — 기초자산 Common Stock (5,833) — 행사가 5.51 | 처분(D) | 5,833 | — | — | 0 | 직접(D) | 아니요 | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| 제출 문서 열기 0001193125-25-322645 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2025년 12월 17일 2025년 12월 17일 제출 | Smeal Benjamin C. Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 파생증권: Stock Option (Right to Buy) — 기초자산 Common Stock (1,125) — 행사가 3.453 | 처분(D) | 1,125 | — | — | 0 | 직접(D) | 아니요 | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| 제출 문서 열기 0001193125-25-322645 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2025년 12월 17일 2025년 12월 17일 제출 | CARLSON MARILYN R. Officer: Chief Medical Officer | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 파생증권: Stock Option (Right to Buy) — 기초자산 Common Stock (17,291) — 행사가 5.27 | 처분(D) | 17,291 | — | — | 0 | 직접(D) | 아니요 | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| 제출 문서 열기 0001193125-25-322644 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2025년 12월 17일 2025년 12월 17일 제출 | CARLSON MARILYN R. Officer: Chief Medical Officer | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 파생증권: Stock Option (Right to Buy) — 기초자산 Common Stock (11,000) — 행사가 4.45 | 처분(D) | 11,000 | — | — | 0 | 직접(D) | 아니요 | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| 제출 문서 열기 0001193125-25-322644 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2025년 12월 17일 2025년 12월 17일 제출 | D'Onofrio Matthew J Director · Officer: Chief Executive Officer | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 파생증권: Stock Option (Right to Buy) — 기초자산 Common Stock (64,840) — 행사가 5.27 | 처분(D) | 64,840 | — | — | 0 | 직접(D) | 아니요 | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| 제출 문서 열기 0001193125-25-322637 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2025년 12월 17일 2025년 12월 17일 제출 | D'Onofrio Matthew J Director · Officer: Chief Executive Officer | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 파생증권: Stock Option (Right to Buy) — 기초자산 Common Stock (70,000) — 행사가 4.45 | 처분(D) | 70,000 | — | — | 0 | 직접(D) | 아니요 | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| 제출 문서 열기 0001193125-25-322637 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2025년 12월 17일 2025년 12월 17일 제출 | Kowieski Mark Officer: Chief Financial Officer | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 파생증권: Stock Option (Right to Buy) — 기초자산 Common Stock (17,291) — 행사가 5.27 | 처분(D) | 17,291 | — | — | 0 | 직접(D) | 아니요 | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| 제출 문서 열기 0001193125-25-322640 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2025년 12월 17일 2025년 12월 17일 제출 | Kowieski Mark Officer: Chief Financial Officer | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 파생증권: Stock Option (Right to Buy) — 기초자산 Common Stock (13,000) — 행사가 4.45 | 처분(D) | 13,000 | — | — | 0 | 직접(D) | 아니요 | F2 - F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
| 제출 문서 열기 0001193125-25-322640 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2025년 12월 17일 2025년 12월 17일 제출 | PYSZCZYMUKA GREG Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 파생증권: Stock Option (Right to Buy) — 기초자산 Common Stock (5,833) — 행사가 5.26 | 처분(D) | 5,833 | — | — | 0 | 직접(D) | 아니요 | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| 제출 문서 열기 0001193125-25-322646 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2025년 12월 17일 2025년 12월 17일 제출 | PYSZCZYMUKA GREG Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 파생증권: Stock Option (Right to Buy) — 기초자산 Common Stock (1,155) — 행사가 3.453 | 처분(D) | 1,155 | — | — | 0 | 직접(D) | 아니요 | F1, F2 - F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
| 제출 문서 열기 0001193125-25-322646 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2025년 12월 16일 2025년 12월 17일 제출 | Hill Malcolm R Director | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | 처분(D) | 133 | — | — | 0 | 직접(D) | 아니요 | F1 - F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
| 제출 문서 열기 0001193125-25-322642 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2025년 12월 16일 2025년 12월 17일 제출 | GARNER CAM L Director | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | 처분(D) | 2,330 | — | — | 0 | 간접(I) By Garner Investments, L.L.C. | 아니요 | F1 - F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
| 제출 문서 열기 0001193125-25-322643 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2025년 12월 16일 2025년 12월 17일 제출 | Brady Todd C Director | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | 처분(D) | 27 | — | — | 0 | 직접(D) | 아니요 | F1 - F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
| 제출 문서 열기 0001193125-25-322639 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2025년 12월 16일 2025년 12월 17일 제출 | CARLSON MARILYN R. Officer: Chief Medical Officer | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | 처분(D) | 360 | — | — | 0 | 직접(D) | 아니요 | F1 - F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
| 제출 문서 열기 0001193125-25-322644 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2025년 12월 16일 2025년 12월 17일 제출 | D'Onofrio Matthew J Director · Officer: Chief Executive Officer | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | 처분(D) | 15,509 | — | — | 0 | 직접(D) | 아니요 | F1 - F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
| 제출 문서 열기 0001193125-25-322637 제출 문서의 XML에서 읽음 이 행에 이의 제기 |
| 2025년 12월 16일 2025년 12월 17일 제출 | Kowieski Mark Officer: Chief Financial Officer | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | 처분(D) | 11,815 | — | — | 0 | 직접(D) | 아니요 | F1 - F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
| 제출 문서 열기 0001193125-25-322640 제출 문서의 XML에서 읽음 이 행에 이의 제기 |